Clinical Trials Logo
  1. Home
  2. CNS Tumor
  3. NCT04773782

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

CNS Tumor Clinical Trial

Official title:
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Clinical Trial Summary

This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA and/or KIT mutation (including non-synonymous point mutations, insertions, and deletions) or amplification, or DMG-H3K27a who have no available curative treatment options. This is a single-arm trial in which all participants will receive avapritinib. The study consists of 2 parts: dose confirmation, safety, and PK (Part 1) and initial efficacy, safety, and PK at the Part 2 recommended dose (Part 2).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04773782
Study type Interventional
Source Blueprint Medicines Corporation
Contact Blueprint Medicines
Phone 617-714-6707
Email medinfo@blueprintmedicines.com
Status Recruiting
Phase Phase 1/Phase 2
Start date February 24, 2022
Completion date April 30, 2025
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06036394 - Artificial Intelligence in CNS Radiation Oncology
Withdrawn NCT05222165 - Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Phase 1/Phase 2
Recruiting NCT03838042 - INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies Phase 1/Phase 2
Recruiting NCT05300113 - Artificial Intelligence Neuropathologist
Completed NCT04334239 - Effectiveness of Care in Certified Cancer Centres in Germany
Active, not recruiting NCT03434262 - SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Phase 1
Withdrawn NCT05952687 - Trial of Idasanutlin and Selinexor Therapy for Children With Progressive/Relapsed AT/RT or Extra-CNS Malignant Rhabdoid Tumors Phase 1
Terminated NCT02988726 - Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma Phase 2
Recruiting NCT04706676 - Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer N/A
Active, not recruiting NCT04023669 - Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors Phase 1
Recruiting NCT05982691 - Development of Asian Consortium for Data Collection and Clinical Trial of CNS Tumors
Recruiting NCT04732065 - ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors Phase 1
Active, not recruiting NCT02684838 - Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry
Recruiting NCT05480904 - Characterizing Sleep Among Long-term Survivors of Childhood Cancer